INTERCEPT PHARMACEUTICALS INC — Form D/A
INTERCEPT PHARMACEUTICALS INC of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2012-09-04. The offering totals $50.0M, of which $30.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2012-09-04
- Form: D/A
- Accession: 0001144204-12-049438
- Industry: Biotechnology
- Exemptions: 06
- Total offering: $50.0M
- Amount sold: $30.0M
- Remaining: $20.0M
- Investors: 2
- Security types: equity
- Revenue range: Decline to Disclose
Issuer
- Name: INTERCEPT PHARMACEUTICALS INC
- CIK: 0001270073
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 18 Desbrosses Street, NEW YORK, NY, 10013
- Phone: 646-747-1000
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Paolo E. Fundaro | Director | New York, NY |
| Mark E. Pruzanski | Director | New York, NY |
| Jonathan T. Silverstein | Director | New York, NY |
| Lorenzo E. Tallarigo | Director | New York, NY |
| Klaus T. Veltinger | Director | New York, NY |
| Nicole E. Williams | Director | New York, NY |
| Luciano E. Adorini | Executive Officer | New York, NY |
| Barbara E. Duncan | Executive Officer | New York, NY |
| Mark E. Pruzanski | Executive Officer | New York, NY |
| David E. Shapiro | Executive Officer | New York, NY |
| Klaus T. Veitinger | Director | New York, NY |
Other filings by this issuer (1)
More